Author: Kleinman, Steve; Stassinopoulos, Adonis
Title: Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation Document date: 2015_8_25
ID: qlddzgbg_32
Snippet: The potential for decreased efficacy of PI-RBCs has not yet been fully assessed and will require Phase III clinical trial data as well as routine use data. For S-303 RBCs, in vitro RBC quality assessment and in vivo volunteer studies indicate that at 35 days of storage, these cells would be expected to function as well as non-PI-RBCs when transfused. With regard to the riboflavin WB system, a full set of similar data is not yet available but prel.....
Document: The potential for decreased efficacy of PI-RBCs has not yet been fully assessed and will require Phase III clinical trial data as well as routine use data. For S-303 RBCs, in vitro RBC quality assessment and in vivo volunteer studies indicate that at 35 days of storage, these cells would be expected to function as well as non-PI-RBCs when transfused. With regard to the riboflavin WB system, a full set of similar data is not yet available but preliminary results suggest that the shelf life of this product may be limited to shorter than 35 days.
Search related documents:
Co phrase search for related documents- clinical trial and volunteer study: 1, 2
- product shelf life and shelf life: 1, 2, 3, 4, 5, 6, 7
- RBC quality and shelf life: 1
- RBC quality assessment and shelf life: 1
- riboflavin WB system and shelf life: 1
Co phrase search for related documents, hyperlinks ordered by date